Alzheimer's Disease Pyroptosis and Gasdermin Inhibitor Companies

Migration, Crosslink

📖

Alzheimer's Disease Pyroptosis and Gasdermin Inhibitor Companies

active

wiki page Created: 2026-04-02T07:20:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-ad-pyroptosis-gasdermin-i

📖 Wiki Page

company1216 wordssynced 2026-04-02

Overview

flowchart TD companies_ad_pyroptosis_gasder["Alzheimers Disease Pyroptosis and Gasdermin Inh"] style companies_ad_pyroptosis_gasder fill:#4fc3f7,stroke:#333,color:#000 companies_ad_pyropto_0["Key Mechanisms"] companies_ad_pyroptosis_gasder -->|"includes"| companies_ad_pyropto_0 style companies_ad_pyropto_0 fill:#81c784,stroke:#333,color:#000 companies_ad_pyropto_1["Caspase-1 Inhibition"] companies_ad_pyroptosis_gasder -->|"includes"| companies_ad_pyropto_1 style companies_ad_pyropto_1 fill:#ef5350,stroke:#333,color:#000 companies_ad_pyropto_2["NLRP3 Inflammasome Inhibition"] companies_ad_pyroptosis_gasder -->|"includes"| companies_ad_pyropto_2 style companies_ad_pyropto_2 fill:#ffd54f,stroke:#333,color:#000 companies_ad_pyropto_3["Gasdermin D Inhibition"] companies_ad_pyroptosis_gasder -->|"includes"| companies_ad_pyropto_3 style companies_ad_pyropto_3 fill:#ce93d8,stroke:#333,color:#000 companies_ad_pyropto_4["IL-1beta/IL-18 Cytokine Blockade"] companies_ad_pyroptosis_gasder -->|"includes"| companies_ad_pyropto_4 style companies_ad_pyropto_4 fill:#4fc3f7,stroke:#333,color:#000 companies_ad_pyropto_5["Key Companies"] companies_ad_pyroptosis_gasder -->|"includes"| companies_ad_pyropto_5 style companies_ad_pyropto_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

This category covers biotechnology and pharmaceutical companies developing therapies targeting pyroptosis and gasdermin pathways for the treatment of Alzheimer's disease. Pyroptosis is a caspase-1 dependent inflammatory cell death pathway characterized by gasdermin D (GSDMD) pore formation that leads to cell swelling, membrane rupture, and release of pro-inflammatory cytokines including IL-1beta and IL-18[@pyroptosis_ad_review][@gsdmd_structure].

The pyroptosis pathway is increasingly recognized as a key contributor to neurodegeneration in AD:

[Amyloid-beta](/proteins/amyloid-beta) deposition activates [NLRP3 inflammasome](/entities/nlrp3-inflammasome) in [microglia](/cell-types/microglia)
[Caspase-1](/proteins/caspase-1-protein) activation cleaves [GSDMD](/proteins/gsdmd-protein) to form pro-inflammatory pores
Neuronal pyroptosis directly contributes to cell loss
Microglial pyroptosis creates chronic [neuroinflammation](/mechanisms/neuroinflammation) that drives disease progression["@gasdermin_neuro"][@nlrp3_ad_review]

Companies in this space pursue several mechanisms:

Caspase-1 inhibition — prevent GSDMD cleavage upstream
NLRP3 inflammasome inhibition — block inflammasome assembly
GSDMD inhibition — target the executioner molecule directly
IL-1beta/IL-18 blockade — downstream cytokine inhibition

Key Mechanisms

Caspase-1 Inhibition

Direct inhibition of caspase-1 prevents GSDMD cleavage and pro-inflammatory cytokine maturation. This is the most upstream intervention point in the pyroptosis pathway.

NLRP3 Inflammasome Inhibition

Block assembly of the NLRP3 inflammasome complex, preventing caspase-1 activation. This approach offers broader anti-inflammatory effects beyond just pyroptosis blockade.

Gasdermin D Inhibition

Direct targeting of GSDMD to prevent pore formation while preserving beneficial inflammasome signaling. Includes small molecules, peptides, and antibody-based approaches.

IL-1β/IL-18 Cytokine Blockade

Downstream inhibition of released pro-inflammatory cytokines. Limited by concerns about CNS penetration but approved drugs offer repurposing opportunities.

Key Companies

Major Pharmaceutical Companies

Eli Lilly and Company

Focus: NLRP3/GSDMD-targeted small molecules
Approach: Internal discovery program targeting neuroinflammation
Related Programs: Multiple CNS inflammation partnerships
Notes: One of the largest pharmaceutical companies with significant AD pipeline including donanemab (anti-amyloid) and other disease-modifying approaches
Related Page: [Eli Lilly](/companies/eli-lilly)

Pfizer Inc.

Focus: Inflammasome modulators and cytokine inhibitors
Approach: Partnerships and internal programs targeting neuroinflammation
Notes: Has exploration programs in NLRP3 inhibition space; established CNS capabilities
Related Page: [Pfizer](/companies/pfizer)

Bristol Myers Squibb (BMS)

Focus: NLRP3 inflammasome and IL-1 pathway inhibition
Approach: Acquisitions and partnerships in inflammation therapeutics
Notes: Strong inflammation portfolio with strategic interest in neurodegeneration; BMS-986253 (anti-IL-8) in development
Related Page: [Bristol Myers Squibb](/companies/bristol-myers-squibb)

Zentalis Pharmaceuticals

Focus: GSDMD-targeted small molecules
Lead Candidate: ZNL-0801 (research program)
Indication: Alzheimer's disease
Stage: Discovery/Preclinical
Mechanism: Direct GSDMD inhibitor designed to block pyroptotic pore formation
Notes: Novel approach directly targeting the executioner of pyroptosis; company known for targeted oncology therapies expanding into neurodegeneration

Biotech Companies with AD Programs

Nodthera Ltd.

Focus: NLRP3 inflammasome inhibition
Lead Candidate: NT-0796
Indication: Alzheimer's disease
Stage: Phase 1/2
Mechanism: Brain-penetrant NLRP3 small molecule inhibitor
Notes: First-in-class oral therapy targeting neuroinflammation; backed byflagship pioneering
Related Page: [Nodthera](/companies/nodthera)

Olatec Therapeutics (Dapansutrile)

Focus: NLRP3 inflammasome inhibition
Lead Candidate: Dapansutrile (OLT1177)
Indication: Alzheimer's disease
Stage: Phase 2
Mechanism: Oral NLRP3 inhibitor with established safety profile in inflammatory conditions
Notes: Well-characterized small molecule with broad anti-inflammatory effects; has shown efficacy in multiple inflammatory conditions
Related Page: [Olatec Therapeutics](/companies/olatec-therapeutics)

IFM Therapeutics

Focus: NLRP3 and GSDMD modulation
Approach: Small molecule programs targeting inflammasome pathways
Stage: Preclinical
Notes: Founded by Atlas Venture; acquired by BMS in 2021 but maintains independent operations; focused on innate immune pathways
Related Page: [IFM Therapeutics](/companies/ifm-therapeutics)

Repurposed Drug Programs

Disulfiram (Various)

Focus: GSDMD inhibition (repurposed)
Indication: ALS, exploratory for AD
Stage: Observational/Preclinical
Mechanism: Known GSDMD inhibitor; blocks pyroptosis execution
Notes: Generic drug with established safety profile; being explored in neurodegenerative diseases

Dimethyl Fumarate (Biogen)

Focus: GSDMD modulation
Indication: Multiple Sclerosis, exploratory for AD
Stage: Approved for MS; Phase 2 in AD
Mechanism: Has shown GSDMD inhibition properties; immunomodulatory effects
Notes: Tecfidera is approved for MS; company exploring neurological applications
Related Page: [Biogen](/companies/biogen)

Antibody-Based Approaches

Canakinumab (Novartis)

Focus: IL-1β antibody
Indication: Alzheimer's disease (exploratory)
Stage: Phase 2
Mechanism: Monoclonal antibody targeting IL-1β, downstream of pyroptosis
Notes: Approved for autoimmune conditions; CNS penetration remains a concern

Anakinra (Swedish Orphan Biovitrum)

Focus: IL-1R antagonist
Indication: Inflammatory conditions, exploratory for neurodegeneration
Stage: Phase 2
Mechanism: Recombinant IL-1 receptor antagonist
Notes: Established safety profile; limited CNS penetration

Emerging Research-Stage Companies

Ventus Therapeutics

Focus: NLRP3 and cGAS-STING inhibition
Lead Candidates: VENT-01, VENT-02
Stage: Discovery
Mechanism: Novel small molecule inflammasome inhibitors
Notes: Precision immunology company targeting innate immune pathways
Related Page: [Ventus Therapeutics](/companies/ventus-therapeutics)

Inception Therapeutics

Focus: Neuroinflammation modulation
Approach: Platform targeting multiple inflammatory pathways
Stage: Discovery
Notes: Focused on microglial modulation and neuroinflammation

Pipeline Overview

| Company | Drug/Mechanism | Target | Indication | Stage |
|---------|---------------|--------|------------|-------|
| Eli Lilly | Small molecule program | NLRP3/GSDMD | AD | Discovery |
| Pfizer | Inflammasome modulators | NLRP3 | AD | Research |
| BMS | NLRP3 program | NLRP3 | Neurodegeneration | Preclinical |
| Zentalis | ZNL-0801 | GSDMD | AD | Discovery |
| Nodthera | NT-0796 | NLRP3 | AD | Phase 1/2 |
| Olatec | Dapansutrile | NLRP3 | AD | Phase 2 |
| IFM Therapeutics | Small molecules | NLRP3/GSDMD | Neurodegeneration | Preclinical |
| Disulfiram (repurposed) | Generic | GSDMD | AD/ALS | Observational |
| Biogen | Dimethyl fumarate | GSDMD | AD | Phase 2 |
| Novartis | Canakinumab | IL-1β | AD | Phase 2 |
| Ventus Therapeutics | VENT-01 | NLRP3 | Neurodegeneration | Discovery |

Cross-Links

[Pyroptosis Pathway](/mechanisms/pyroptosis) — Primary mechanism page
[Pyroptosis in Neurodegeneration](/mechanisms/pyroptosis-neurodegeneration) — Disease-specific mechanisms
[NLRP3 Inflammasome](/entities/nlrp3-inflammasome) — Inflammasome biology
[GSDMD Protein](/proteins/gsdmd-protein) — Gasdermin D page
[Caspase-1](/proteins/caspase-1-protein) — Protease page
[Neuroinflammation in AD](/mechanisms/neuroinflammation-ad) — General inflammation

[Pyroptosis Inhibition Therapy](/therapeutics/pyroptosis-inhibition-therapy) — Therapeutic compounds
[Pyroptosis Modulation Therapy](/therapeutics/pyroptosis-modulation-therapy) — Therapeutic approaches
[NLRP3 Inflammasome Inhibitors](/mechanisms/nlrp3-inflammasome-inhibitors-parkinsons) — Related inhibitors

[AD Neuroinflammation Companies](/companies/ad-neuroinflammation-companies) — Broader neuroinflammation
[AD Ferroptosis Companies](/companies/ad-ferroptosis-companies) — Related cell death pathways
[cGAS-STING Innate Immune Companies](/companies/ad-cgas-sting-innate-immune-companies) — Related innate immunity

Investment Pages

[Pyroptosis Inhibitors for Neurodegeneration](/investment/pyroptosis-inhibitors-neurodegeneration) — Investment landscape analysis

Scientific Rationale

Pyroptosis in Alzheimer's Disease

The involvement of pyroptosis in AD is supported by multiple lines of evidence:

Amyloid-beta activation: Aβ directly activates NLRP3 inflammasome in microglia, triggering caspase-1 activation and GSDMD cleavage[@nlrp3_ad_review]

Tau pathology synergy: Phosphorylated tau promotes GSDMD cleavage, creating a feed-forward loop between tau pathology and pyroptotic cell death

Neuronal vulnerability: Neurons in AD-vulnerable regions show enhanced susceptibility to pyroptotic death

Microglial dysfunction: Microglial pyroptosis leads to loss of supportive functions and creates chronic neuroinflammation

Genetic links: NLRP3 and related gene variants are associated with AD risk

Therapeutic Rationale

Blocking pyroptosis offers dual benefits:

Prevent cell death: Block GSDMD-mediated neuronal loss
Reduce inflammation: Prevent release of IL-1β, IL-18, and other pro-inflammatory mediators

This makes pyroptosis inhibition an attractive disease-modifying approach for AD.

References

[Tan et al., Pyroptosis in Alzheimer's disease: mechanisms and therapeutic potential (2023)](https://pubmed.ncbi.nlm.nih.gov/37258914/)

[Gasdermin D in neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[NLRP3 inflammasome in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37612420/)

[Liu et al., Gasdermin D: the executioner of pyroptotic cell death (2020)](https://pubmed.ncbi.nlm.nih.gov/32272060/)

📖 View canonical wiki page →

Related Entities

companies-ad-pyroptosis-gasdermin-inhibitor-companies

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-ad-pyroptosis-gasdermin-inhibitor-companies
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-873b03de2498
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-ad-pyroptosis-gasdermin-inhibitor-companies'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

482

Outgoing

492

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Alzheimer's Disease Pyroptosis and Gasdermin Inhibitor Companies

Overview

Overview

Key Mechanisms

Caspase-1 Inhibition

NLRP3 Inflammasome Inhibition

Gasdermin D Inhibition

IL-1β/IL-18 Cytokine Blockade

Key Companies

Major Pharmaceutical Companies

Eli Lilly and Company

Pfizer Inc.

Bristol Myers Squibb (BMS)

Zentalis Pharmaceuticals

Biotech Companies with AD Programs

Nodthera Ltd.

Olatec Therapeutics (Dapansutrile)

IFM Therapeutics

Repurposed Drug Programs

Disulfiram (Various)

Dimethyl Fumarate (Biogen)

Antibody-Based Approaches

Canakinumab (Novartis)

Anakinra (Swedish Orphan Biovitrum)

Emerging Research-Stage Companies

Ventus Therapeutics

Inception Therapeutics

Pipeline Overview

Cross-Links

Investment Pages

Scientific Rationale

Pyroptosis in Alzheimer's Disease

Therapeutic Rationale

See Also

References

💬 Discussion

📗 Cite This Artifact

Alzheimer's Disease Pyroptosis and Gasdermin Inhibitor Companies

Overview

Overview

Key Mechanisms

Caspase-1 Inhibition

NLRP3 Inflammasome Inhibition

Gasdermin D Inhibition

IL-1β/IL-18 Cytokine Blockade

Key Companies

Major Pharmaceutical Companies

Eli Lilly and Company

Pfizer Inc.

Bristol Myers Squibb (BMS)

Zentalis Pharmaceuticals

Biotech Companies with AD Programs

Nodthera Ltd.

Olatec Therapeutics (Dapansutrile)

IFM Therapeutics

Repurposed Drug Programs

Disulfiram (Various)

Dimethyl Fumarate (Biogen)

Antibody-Based Approaches

Canakinumab (Novartis)

Anakinra (Swedish Orphan Biovitrum)

Emerging Research-Stage Companies

Ventus Therapeutics

Inception Therapeutics

Pipeline Overview

Cross-Links

Related Mechanisms

Related Therapeutics

Related Company Categories

Investment Pages

Scientific Rationale

Pyroptosis in Alzheimer's Disease

Therapeutic Rationale

See Also

References

💬 Discussion